Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

HEPATITIS B
According to current statistics, hepatitis B is the most common infectious disease in the world, affecting some 2 billion people -- that's more than one-quarter of the world's population. This disease, which is characterized by an inflammation of the liver that leads to jaundice, nausea, and fatigue, can lead to long-term complications such as cirrhosis of the liver or even liver cancer. The concern is primarily for those who carry the chronic form of the disease, which is estimated to be about 350 million people.

https://www.fool.com/investing/general/2013/12/29/the-5-most-common-infectious-diseases.aspx

VASOACTIVE INTESTINAL PEPTIDE (VIP) has recently been shown to bind to human lymphocytes and modulate immune functions. The ability of VIP in restoring natural killer (NK) cell activity depressed by hepatitis B surface antigen (HBsAg) has been investigated in the present research.

https://pubmed.ncbi.nlm.nih.gov/1418317/

The global hepatitis therapeutics market size was estimated at USD 21.9 billion in 2019 and is expected to reach USD 22.5 billion in 2020.

https://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market

CARDIOVASCULAR DISEASE
Studies from around the world link heart disease to poverty. Low neighborhood income and education were associated with higher risk factors. Poor diet, lack of exercise and limited (or no) access to a specialist were all factors related to poverty, though to contribute to heart disease.

https://en.wikipedia.org/wiki/Diseases_of_poverty

The presence and SIGNIFICANT CARDIOVASCULAR EFFECTS of VIP in the heart suggests that this peptide is important in the regulation of coronary blood flow, cardiac contraction, and heart rate. Current investigations are defining the physiological role of VIP in the regulation of cardiovascular function.

https://pubmed.ncbi.nlm.nih.gov/11121793/

The global cardiovascular drugs market is expected to grow from $87.79 billion in 2020 to $92.41 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%.

https://www.globenewswire.com/en/news-release/2021/05/17/2230401/28124/en/Insights-on-the-87-Billion-Cardiovascular-Drugs-Global-Market-to-2030-Identify-Growth-Segments-for-Investment.html